Genmab A/S (NASDAQ:GMAB) Raised to Hold at BNP Paribas

Genmab A/S (NASDAQ:GMAB) was upgraded by investment analysts at BNP Paribas from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities research analysts also recently commented on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday. Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $19.69 on Tuesday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The company has a market cap of $13.03 billion, a P/E ratio of 19.12, a PEG ratio of 0.54 and a beta of 0.96. The stock’s fifty day moving average price is $20.68 and its 200-day moving average price is $23.21.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. On average, sell-side analysts anticipate that Genmab A/S will post 1.25 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several hedge funds have recently bought and sold shares of the stock. Legacy Wealth Asset Management LLC boosted its holdings in Genmab A/S by 1.1% in the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after buying an additional 471 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after buying an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC grew its stake in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.